Purple Biotech Ltd. announced research collaboration with Mor Research Applications (Mor), the technology transfer subsidiary of Clalit Healthcare Services (Clalit). The agreement provides Purple Biotech first access to early-stage oncology product candidates owned by Mor. Under this agreement, the Company will have the option to fund early development aiming both to in-license selected drug assets and to pursue their development and commercialization.

The research conducted at these hospitals is now potentially available to Purple Biotech for in-licensing and clinical development. Under this partnership, Purple Biotech has first right to review Mor's pool of early-stage research projects and to select those that it wishes to explore in early development prior to in-licensing, which will carry worldwide exclusivity.